Business Secretary Dr Vince Cable has visited the Manchester Institute of Biotechnology (MIB) to meet scientists working on synthetic biology. This follows the announcement of £40million funding into this cutting-edge research area, £32 million of which is being split across new research centres in Manchester, Edinburgh, and Warwick.

The investment comes from the Biotechnology and Biological Sciences Research Council (BBSRC), the Engineering and Physical Sciences Research Council (EPSRC), and the Medical Research Council (MRC), as well as via capital investment from the UK government. Funds will be awarded over a five-year period, boosting national research capacity and ensuring that the expertise to nurture this growing industry exists in the UK.

The MIB will receive £10.3million to establish the Centre for Synthetic Biology of Fine and Speciality Chemicals (SYNBIOCHEM). This centre will develop new products and methods for drug discovery and production, agricultural chemicals, and new materials for sustainable manufacturing. Professor Nigel Scrutton, Co-Director of SYNBIOCHEM, said:/

“Our vision is to harness the power of synthetic biology to propel chemicals and natural products production towards ‘green’ and sustainable manufacturing processes. More broadly, the Centre will provide the general tools, technology platforms, and ‘know-how’ to drive academic discovery and translate new knowledge and processes towards industrial exploitation.”

Synthetic biology is a new scientific method that applies engineering principles to biology to create new biological parts, devices, and systems. It has been used to generate biological ‘factories’ producing useful products such as medicines, chemicals, green energy, and tools for improving crops. It has been identified by the government as one of ‘Eight Great Technologies’ in which Great Britain can be a world leader. Fellow Co-Director, Professor Eriko Takano, added:

“Synthetic biology is an emerging science that has the capacity to transform the UK and European industrial landscape. It will revolutionise manufacturing processes to deliver renewable and sustainable materials, biopharmaceuticals, chemicals, and energy that will impact significantly on our economic, social, and environmental landscape. It promises a brighter future for all.”